Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Clinical trials

Harmony Biosciences
Regional

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome

April 14, 2025April 14, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The …

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome Read More

Palvella Therapeutics
Research

Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder

April 12, 2025April 11, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ rapamycin 3.9% anhydrous gel for microcystic lymphatic malformations (microcystic LMs) at the 15th World …

Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder Read More
Context Therapeutics
Regional

Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers

April 10, 2025April 9, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 clinical trial of CT-95, a bispecific antibody designed to target …

Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers Read More

AstraZeneca
Regional

AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial

April 7, 2025April 6, 2025 - by Timothy Alexander

WILMINGTON, DE — New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers significant reductions in LDL cholesterol (LDL-C) when combined with standard-of-care statin …

AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial Read More
Johnson & Johnson
Regional

Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis Study

April 6, 2025April 6, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), revealing its effectiveness in treating active psoriatic arthritis (PsA). The …

Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis Study Read More

Aprea Therapeutics
Regional

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing

April 2, 2025April 1, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) …

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing Read More
Johnson & Johnson
Regional

Johnson & Johnson Showcases Promising Data on Nipocalimab for gMG at AAN Annual Meeting

March 29, 2025March 28, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology (AAN) Annual Meeting, providing insight into its potential to …

Johnson & Johnson Showcases Promising Data on Nipocalimab for gMG at AAN Annual Meeting Read More

Teleflex Incorporated
Research

Teleflex Reports Promising Preliminary Results for Ringer PBC Study

March 28, 2025March 27, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has shared promising preliminary results from its Ringer™ PBC IDE study, featured in a presentation at the CTO Plus Conference in New York. The …

Teleflex Reports Promising Preliminary Results for Ringer PBC Study Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress

March 27, 2025March 26, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight the latest findings from its pivotal Advance-HTN and Launch-HTN clinical trials. The event …

Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress Read More
Annovis Bio
Research

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025

March 27, 2025March 26, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More

Posts pagination

Previous 1 … 15 16 17 … 35 Next

Trending News

  • Crashes, DUI Arrests, and Investigations Crowd PSP Avondale Blotter

  • Two Chester County Graduates Prove You Can Get Ahead Without Leaving Home

  • Planned Tree Removal to Close Newark Road, Forcing Detours in Chester County

  • Hidden in Plain Sight: CBP Busts Six Ketamine Smuggling Attempts at Philly Hub

  • Invisible Killer Lurks Indoors: Radon Found at Dangerous Levels in PA Homes

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Pennsylvania State Police

Crashes, DUI Arrests, and Investigations Crowd PSP Avondale Blotter

December 30, 2025December 30, 2025

PHL Ketamine

Hidden in Plain Sight: CBP Busts Six Ketamine Smuggling Attempts at Philly Hub

December 30, 2025December 30, 2025

East Lea Boulevard

Deadly Hit-and-Run on Wilmington Street Leaves Woman Dead, Driver Vanishes

December 30, 2025December 30, 2025

Copyright © 2025 MyChesCo.